Pharmaceutical Contract Management Consulting in the US - Industry Market Research Report

Another Dose: Growing Corporate Profit and Healthcare Expenditures Will Likely Support Industry Growth

Over the past five years, the patent cliff, an ongoing series of expiration dates for the patents on blockbuster drugs, has stimulated the volume of research and development (R&D) work outsourced by generic pharmaceutical and biotechnology companies, promoting growth for consultants. The outbreak of COVID-19 led to growth for consultants as pharmaceutical manufacturers ramped up R&D expenditures to develop new drugs and looked to consultants to sure up their operations. Industry-wide revenue has been climbing at a CAGR of 1.0% over the past five years and is expected to total $37.6 billion in 2023, when revenue will jump by an estimated 4.1%.

This industry provides consulting to pharmaceutical companies, which includes the assessment of cost structures and client contracting processes. Firms ensure compliance and track performance. This can include the development and implementation of software for these purposes.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry's key players and their market shares.